Fred Lublin

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Magnetic resonance imaging of meningoradiculomyelitis in early disseminated Lyme disease
    Mark J Tullman
    Departments of Neurology and Neuroradiology, Mount Sinai School of Medicine, New York, New York, USA
    J Neuroimaging 13:264-8. 2003
  2. ncbi request reprint Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal
    Krupa Pandey
    Fred D Lublin, MD Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street, Box 1138, New York, NY 10029, USA
    Curr Treat Options Neurol 11:193-202. 2009
  3. pmc Atypical Chédiak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease
    James D Weisfeld-Adams
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA
    Orphanet J Rare Dis 8:46. 2013
  4. pmc Randomized study combining interferon and glatiramer acetate in multiple sclerosis
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY
    Ann Neurol 73:327-40. 2013
  5. ncbi request reprint The incomplete nature of multiple sclerosis relapse resolution
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, 5 East 98th Street, Box 1138, New York, New York 10029, USA
    J Neurol Sci 256:S14-8. 2007
  6. ncbi request reprint Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS
    F D Lublin
    Department of Neurology, Mount Sinai School of Medicine, New York 10029 6574, USA
    Ann Neurol 49:677-81. 2001
  7. ncbi request reprint Multiple sclerosis trial designs for the 21st century: building on recent lessons
    Fred Lublin
    Saunders Family Professor of Neurology, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, 5 East 98th Street, 1138, New York, NY 10029 6574, USA
    J Neurol 252:v46-53. 2005
  8. ncbi request reprint History of modern multiple sclerosis therapy
    Fred Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    J Neurol 252:iii3-iii9. 2005
  9. ncbi request reprint Clinical features and diagnosis of multiple sclerosis
    Fred D Lublin
    Mount Sinai Medical Center, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street, Box 1138, New York, NY 10029 6574, USA
    Neurol Clin 23:1-15, v. 2005
  10. ncbi request reprint When marketing and science intersect: do patients with MS benefit?
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Neurology 59:1480-1. 2002

Research Grants

  1. Combination Therapy in Multiple Sclerosis
    Fred Lublin; Fiscal Year: 2007

Detail Information

Publications29

  1. ncbi request reprint Magnetic resonance imaging of meningoradiculomyelitis in early disseminated Lyme disease
    Mark J Tullman
    Departments of Neurology and Neuroradiology, Mount Sinai School of Medicine, New York, New York, USA
    J Neuroimaging 13:264-8. 2003
    ..The authors present the clinical and radiographic findings, both before and after treatment, in a patient with meningoradiculomyelitis due to early disseminated Lyme disease...
  2. ncbi request reprint Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal
    Krupa Pandey
    Fred D Lublin, MD Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street, Box 1138, New York, NY 10029, USA
    Curr Treat Options Neurol 11:193-202. 2009
    ..Treatment should also be initiated early in patients with clinically isolated syndrome because they are at high risk for developing clinically definite multiple sclerosis...
  3. pmc Atypical Chédiak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease
    James D Weisfeld-Adams
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA
    Orphanet J Rare Dis 8:46. 2013
    ....
  4. pmc Randomized study combining interferon and glatiramer acetate in multiple sclerosis
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY
    Ann Neurol 73:327-40. 2013
    ....
  5. ncbi request reprint The incomplete nature of multiple sclerosis relapse resolution
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, 5 East 98th Street, Box 1138, New York, New York 10029, USA
    J Neurol Sci 256:S14-8. 2007
    ....
  6. ncbi request reprint Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS
    F D Lublin
    Department of Neurology, Mount Sinai School of Medicine, New York 10029 6574, USA
    Ann Neurol 49:677-81. 2001
    ..Patients who decline to utilize available treatments, after proper education and counseling, or those that fail all therapies can be considered to have no treatment alternatives and thus may participate in a placebo-controlled trial...
  7. ncbi request reprint Multiple sclerosis trial designs for the 21st century: building on recent lessons
    Fred Lublin
    Saunders Family Professor of Neurology, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, 5 East 98th Street, 1138, New York, NY 10029 6574, USA
    J Neurol 252:v46-53. 2005
    ..In addition to the increased need for enhanced safety assessment, this issue will have an impact both on the study of combination therapies and on the use of combinations in clinical practice...
  8. ncbi request reprint History of modern multiple sclerosis therapy
    Fred Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    J Neurol 252:iii3-iii9. 2005
    ..There is now a much better understanding of the pathogenesis of the disease, but new and improved therapeutic approaches are still needed...
  9. ncbi request reprint Clinical features and diagnosis of multiple sclerosis
    Fred D Lublin
    Mount Sinai Medical Center, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street, Box 1138, New York, NY 10029 6574, USA
    Neurol Clin 23:1-15, v. 2005
  10. ncbi request reprint When marketing and science intersect: do patients with MS benefit?
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Neurology 59:1480-1. 2002
  11. ncbi request reprint Effect of relapses on development of residual deficit in multiple sclerosis
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
    Neurology 61:1528-32. 2003
    ..To determine the percentage of patients with residual deficits following multiple sclerosis (MS) exacerbations and the magnitude of those deficits using a database of pooled placebo patients from clinical trials...
  12. doi request reprint Multiple sclerosis: new treatment trials and emerging therapeutic targets
    Tracy DeAngelis
    Department of Neurology, Mount Sinai School of Medicine New York, New York, USA
    Curr Opin Neurol 21:261-71. 2008
    ..This review focuses on new therapeutic strategies in multiple sclerosis...
  13. ncbi request reprint Combination therapy in multiple sclerosis
    Mark J Tullman
    The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Neurol Neurosci Rep 5:245-8. 2005
    ..Rigorously controlled studies are needed to determine the safest and most effective use of new and existing MS therapies...
  14. ncbi request reprint The diagnosis of multiple sclerosis
    Fred D Lublin
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY, USA
    Curr Opin Neurol 15:253-6. 2002
    ..These new guidelines should provide for the earlier and easier diagnosis of multiple sclerosis, useful for both clinical trials and neurological practice...
  15. ncbi request reprint Use of interferon-beta in the treatment of multiple sclerosis
    Joy Derwenskus
    Department of Neurology, Northwestern University, Chicago, Illinois, USA
    Adv Neurol 98:257-71. 2006
  16. doi request reprint Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium
    Ilya Kister
    Multiple Sclerosis Care Center, Department of Neurology, New York University School of Medicine, NYU Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003 3804, USA
    Mult Scler 17:725-33. 2011
    ..Although the natural history of multiple sclerosis has been charted extensively, it is still not known whether the trajectory of disability accumulation has changed in the era of disease-modifying therapies (DMTs)...
  17. ncbi request reprint Immunotherapy of multiple sclerosis--current practice and future directions
    Mark J Tullman
    The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
    J Rehabil Res Dev 39:273-85. 2002
    ..Although effective, these therapies have a modest impact on reduction in relapse rate and slowing of disease progression. Much work is needed to improve upon this modest effect and hopefully obtain a cure...
  18. doi request reprint Differentiating multiple sclerosis from other causes of demyelination using diffusion weighted imaging of the corpus callosum
    Rebecca Straus Farber
    Mount Sinai Medical Center, Department of Neurology, New York, NY 10029, USA
    J Magn Reson Imaging 30:732-6. 2009
    ....
  19. doi request reprint Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies
    Tracy DeAngelis
    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 75:157-67. 2008
    ..This review will highlight recent promising therapeutic strategies under investigation in the field of MS...
  20. doi request reprint A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
    ..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
  21. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  22. ncbi request reprint Health-related quality of life in multiple sclerosis: effects of natalizumab
    Richard A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 62:335-46. 2007
    ..To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab...
  23. ncbi request reprint Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:911-23. 2006
    ..Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies...
  24. ncbi request reprint A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
  25. ncbi request reprint Evaluating multiple sclerosis
    Mark J Tullman
    J Neurol Sci 218:1-2. 2004
  26. ncbi request reprint Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
    A John Petkau
    Department of Statistics, University of British Columbia, 333 6356 Agricultural Road, Vancouver, British Columbia, Canada V6T 1Z2
    Mult Scler 10:126-38. 2004
    ..In these patients, the influence of NABs may be self-limited, as titers often diminish or NABs become undetectable with time...
  27. doi request reprint Responsiveness and predictive values in PPMS: an uncertain message
    Gary R Cutter
    Neurology 70:1061-2. 2008
  28. ncbi request reprint Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"
    Chris H Polman
    VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Neurol 58:840-6. 2005
    ..The 2005 Revisions to the McDonald Diagnostic Criteria for MS should simplify and speed diagnosis, whereas maintaining adequate sensitivity and specificity...
  29. ncbi request reprint Quantitative functional MR imaging of the visual cortex at 1.5 T as a function of luminance contrast in healthy volunteers and patients with multiple sclerosis
    Scott H Faro
    Department of Radiological Sciences, MCP Hahnemann University, 3300 Henry Ave, Philadelphia, PA 19129, USA
    AJNR Am J Neuroradiol 23:59-65. 2002
    ..We therefore investigated whether varying luminance contrast levels can help uncover subtle changes in fMR imaging characteristics of the visual cortex in healthy volunteers and patients with MS...

Research Grants2

  1. Combination Therapy in Multiple Sclerosis
    Fred Lublin; Fiscal Year: 2007
    ..The trial design to be employed will serve as a standard for comparing and combining any of the therapeutic agents for treatment of MS and will provide longer-term data than any prior controlled MS trial. ..